Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced
Hormone-dependent Prostate Carcinoma. The period until Prostate Specific Antigen (PSA)
progression during the Firmagon® therapy is to be documented and related to the testosterone
values measured in the course of therapy (if available). Other clinical parameters, the
patients' quality of life and the direct and indirect costs incurred by the medical care for
the advanced hormone-dependent prostate carcinoma and its consequences will be evaluated. In
this context the medical outcome and the life quality are defined as effectiveness and
benefit value parameters. Both the effectiveness under daily life circumstances and economic
variables of the therapy can thus be shown and compared within an analysis of costs vs.
benefits or costs vs. effectiveness.